Pharma Focus Asia
Klöckner Pentaplast - Pentapharm® alfoil® films

New Pharma Business Models

Regaining power

Prasanthi Potluri, Editor Pharma Focus Asia

Changing patterns of diseases, ageing population, price controls, dry R&D pipelines, patent expirations for many blockbuster drugs and declining global generic market opportunities are a wake-up call for pharma. Moreover, the shift in focus to improved outcomes is pushing pharma companies to rethink on the existing business models for more productive R&D solutions at low costs.

To achieve this, pharma companies need to move from a traditional pharmaceutical company to becoming a fully integrated pharmaceutical network. A fully integrated network focuses on different therapeutic areas covering R&D to sales and marketing, different enabling technologies, such as genomics, proteomics and stem cell research; and management of outcomes.

Increased spending on R&D will help companies to refresh their pipelines. According to Battelle and R&D Magazine, R&D spending in the global life science industry is expected to rise more than 3 per cent to US$201 billion in 2014. The biopharmaceuticals industry will account for about 85 per cent of that total, with top US spenders including Pfizer, Merck, and Johnson & Johnson, as well as European giants Novartis and Roche.

New formulations with shorter patent lives are due to expire very soon causing scarcity in block-buster drugs for patients. Hence, the industry will have to spend exclusively to protect patents and for better patenting patterns.

In addition to this, collaborations, alliances with smaller biotechnology companies and better biotechnology and pharmaceutical outsourcing options will develop effective new medicines more economically.

The cover story in this issue by Patrick Flochel, EY Global Pharmaceutical Sector Leader traces how pricing and regulatory challenges are changing the business model from Pharma 1.0 to Pharma 2.0. The article also highlights how this transformation is impacting pharma companies' operations. Changing incentives are reshaping the healthcare ecosystem and Pharma 3.0's new focus on healthcare outcome is opening doors for non-traditional players.

Employing these strategies and proactively tackling challenges will become decisive for the future of pharma industry in its attempt to regain the power and meet the promises.

-- Issue 20 --

Author Bio

Prasanthi Potluri
magazine-slider-imageBIOVIA from Molecule to MedicineMFA + MMA 2024CPHI China || PMEC China 2024Asia Healthcare Week 2024Advance DoE WorkshopCPHI Korea 2024CHEMICAL INDONESIA 2024INALAB 2024 Thermo Scientific - DynaDrive and DynaSpinRehab Expo 2024ISPE Singapore Affiliate Conference & Exhibition 20242024 PDA Cell and Gene Pharmaceutical Products Conference 2024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals Conference3rd World ADC Asia 2024LogiPharma Asia 2024